Polio endgame: the global introduction of inactivated polio vaccine

References

• Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx [Last accessed 5 January 2014]
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine 2010;29(2):334-43
   PubMed Web of Science ®Google Scholar
• Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th edition. Elsevier, Philadelphia, PA, USA; 2013. p. 598-645
   Google Scholar
• Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012;11(4):449-59
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013;33(4):680-702
   PubMed Web of Science ®Google Scholar
• Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587-635
   PubMed Web of Science ®Google Scholar
• Vidor E, Plotkin SA. Poliovirus vaccine - inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccine. 6th edition. Elsevier; Philadelphia: 2013. p. 573-97
   Google Scholar
• Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8(4):e1002599
   PubMed Web of Science ®Google Scholar
• Herremans MM, van Loon AM, Reimerink JH, et al. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol 1997;4(5):499-503
   PubMedGoogle Scholar
• Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014;345(6199):922-5
   PubMed Web of Science ®Google Scholar
• Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991;163(1):1-6
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. WHO/POLIO/13.02. 2013. Available from: www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf [Last accessed 22 July 2014]
   Google Scholar
• Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2012;87(21):201-16
   PubMedGoogle Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2013;88(1):1-16
   PubMedGoogle Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2013 - conclusions and recommendations. Wkly Epidemiol Rec 2013;88(20):201-6
   PubMedGoogle Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010;85(23):213-28
   PubMedGoogle Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2013 – conclusions and recommendations. Wkly Epidemiol Rec 2014;89(1):1-20
   PubMedGoogle Scholar
• Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006;26(6):1471-505
   PubMed Web of Science ®Google Scholar
• Cochi SL, Freeman A, Guirguis S, et al. Global polio eradication initiative: lessons learned and legacy. J Infect Dis 2014;210(Suppl 1):S540-6
   PubMed Web of Science ®Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380-9
   PubMed Web of Science ®Google Scholar
• Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14(2):568-79
   PubMed Web of Science ®Google Scholar
• Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx [Last accessed 15 January 2014]
   Google Scholar
• World Health Organization. 7th Meeting of the SAGE Polio Working Group, WHO, Geneva, 7-8 October 2013. Available from: www.who.int/immunization/sage/meetings/2013/november/3_SAGE_Note_for_the_Record_exec_summary.pdf [Last accessed 26 June 2014]
   Google Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on immunization, October 2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014;89(50):561-76
   PubMedGoogle Scholar
• World Health Organization. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for national policy makers in OPV-using countries (WHO/POLIO/05.02). World Health Organization Geneva, Switzerland; 2005
   Google Scholar
• Mas Lago P, Caceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol 2001;30(5):1029-34
   PubMed Web of Science ®Google Scholar
• Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res 2003;118:217-23
   PubMed Web of Science ®Google Scholar
• Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC). Prevention. Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013. MMWR Morb Mortal Wkly Rep 2014;63(11):242-8
   PubMed Web of Science ®Google Scholar
• Robertson S. Poliomyelitis. In: WHO, editor. Immunological basis for immunization. World Health Organization; Geneva: 1993. p. 1-24. Available from: http://www.who.int/ihr/polio1993en.pdf [Last accessed 5 January 2015]
   Google Scholar
• Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013;3(3):309-15
   PubMed Web of Science ®Google Scholar
• Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014;210(Suppl 1):S439-46
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013;368(5):416-24
   PubMed Web of Science ®Google Scholar
• Sutter RW, Pallansch MA, Sawyer LA, et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995;754:289-99
   PubMed Web of Science ®Google Scholar
• Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;1(8591):897-9
   PubMed Web of Science ®Google Scholar
• Kapusinszky B, Molnar Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol 2010;58(2):211-17
   PubMedGoogle Scholar
• World Health Organization. Scientific evidence in support of: 5th Meeting of the SAGE Working Group, WHO, Geneva, September 3-4, 2012. Available from: www.who.int/immunization/sage/meetings/2012/november/3__SAGE_WG_Scientific_Evidence22Oct2012.pdf [Last accessed 26 June 2014]
   Google Scholar
• Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis 1984;6(Suppl 2):S413-18
   Google Scholar
• Estivariz CF, Molnar Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011;174(3):316-25
   PubMed Web of Science ®Google Scholar
• Kohler KA, Banerjee K, Gary Hlady W, et al. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002;80(3):210-16
   PubMed Web of Science ®Google Scholar
• John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014;384(9953):1505-12
   PubMed Web of Science ®Google Scholar
• Cuba IPVSCG. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007;356(15):1536-44
   PubMed Web of Science ®Google Scholar
• World Health Organization unpublished data, presented at SAGE. Available from: www.who.int/immunization/sage/meetings/2012/november/3__SAGE_WG_Scientific_Evidence22Oct2012.pdf
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210(Suppl 1):S485-97
   PubMedGoogle Scholar
• Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993;341(8860):1545-50
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012;12(2):128-35
   PubMed Web of Science ®Google Scholar
• Available from: www.who.int/immunization/diseases/poliomyelitis/inactivated_polio_vaccine/en/[Last accessed 15 January 2014]
   Google Scholar
• Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother 2013;9(9):1894-902
   PubMed Web of Science ®Google Scholar
• WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014;89(21):221-36
   PubMedGoogle Scholar
• Available from: www.unicef.org/supply/index_66260.html [Last accessed 15 January 2014]
   Google Scholar
• Available from: www.who.int/immunization/diseases/poliomyelitis/inactivated_polio_vaccine/MDVP_Nov2014.pdf?ua=1 [Last accessed 21 November 2014]
   Google Scholar
• World Health Organization. Expanded Program on Immunization: WHO Policy Statement: Multi-dose Vial Policy (MDVP). Available from: http://apps.who.int/iris/bitstream/10665/135972/1/WHO_IVB_14.07_eng.pdf [Last accessed 5 January 2015]
   Google Scholar
• Available from: www.gavialliance.org/support/nvs/inactivated-polio-vaccine/ [Last accessed 15 January 2014]
   Google Scholar
• World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme, 2014. Available from: www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/ [Last accessed 26 June 2014]
   Google Scholar
• Available from: www.unicef.org/supply/files/Product_Menu_March_2014.pdf [Last accessed 15 January 2014]
   Google Scholar
• World Health Organization. Temperature sensitivity of vaccines (WHO/IVB/06.10). World Health Organization Geneva, Switzerland; 2006
   Google Scholar
• World Health Organization. Preventing freeze damage to vaccines. Available from: whqlibdoc.who.int/hq/2007/WHO_IVB_07.09_eng.pdf [Last accessed 26 June 2014]
   Google Scholar
• Wallace AS, Mantel C, Mayers G, et al. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine 2014;32(41):5301-10
   PubMed Web of Science ®Google Scholar
• Available from: www.who.int/immunization/global_vaccine_action_plan/SAGE_DoV_GVAP_Assessment_report_2014_English.pdf?ua=1 [Last accessed 21 November 2014]
   Google Scholar
• Hickling J, Jones R, Nundy N. Improving the Affordability of Inactivated Poliovirus Vaccine (IPV) for use in Low- and Middle-Income Countries. 2012. Available from: www.path.org/publications/detail.php?i=1809 [Last accessed 9 December 2013]
   Google Scholar
• Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012;16(2):e110-16
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362(25):2351-9
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012;205(2):237-43
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, van Oijen MG, et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine 2013;31(47):5531-6
   PubMed Web of Science ®Google Scholar
• Shirato H, Someya Y, Ochiai M, et al. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32(40):5163-9
   PubMed Web of Science ®Google Scholar
• Available from: http://ibb.gatech.edu/hg_news/72457 [Last accessed 26 June 2014]
   Google Scholar
• Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009;333:369-93
   PubMedGoogle Scholar
• World Health Organization. Sixty-seventh World Health Assembly: poliomyelitis: intensification of the global eradication initiative. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_38-en.pdf [Last accessed 11 September 2014]
   Google Scholar
• Available from: www.polioeradication.org/Portals/0/Wild_poliovirus_list_2009_2014_09DEC.pdf
   Google Scholar
• Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx
   Google Scholar